Generic J9041

BORTEZOMIB 3.5 MG VIAL

BORTEZOMIB 3.5 MG VIAL, a generic cancer medication, has an acquisition cost of $43.35, though hospitals typically charge patients several times this benchmark amount.

By Michael Glenn , Healthcare Data Analyst · Published March 15, 2026 · Updated April 3, 2026

Data from CMS files published FY 2024 CMS IPPS. Refreshed weekly.

About the analyst

Michael Glenn reviews CMS datasets and drug pricing at BillRazor Research. He focuses on NADAC acquisition costs and procedure coding accuracy. Expertise: drug pricing, NADAC data, CPT coding.

NADAC acquisition cost data

CMS drug pricing benchmarks

Updated 2026-04-03

Drug acquisition cost — BORTEZOMIB 3.5 MG VIAL

Hospital charges for this drug vary — typically 3–8x the acquisition cost. No observed hospital charge data is available for this specific drug.

$43.35

NADAC acquisition cost

INJECTABLE

Dosage form

INTRAVENOUS, SUBCUTANEOUS

Route

Bortezomib is a cancer treatment medication used for multiple myeloma and mantle cell lymphoma, typically administered through injection. This specialty oncology drug often shows significant price variation between hospital outpatient departments and physician office settings, with potential billing differences exceeding $2,000 per vial.

Check your bill amount

Enter the charge for BORTEZOMIB 3.5 MG VIAL from your bill to compare against the NADAC acquisition cost.

No credit card required. Results in 60 seconds.

Compare your bill against the $43 NADAC acquisition cost → Scan your bill

Research suggests 49–80% of hospital bills contain errors. Our system checks every line item against Medicare benchmarks.

Rates shown are from the 2026 Medicare Physician Fee Schedule and CMS IPPS. BillRazor compares your bill against these data sources. See how it works →

Data source: National Average Drug Acquisition Cost (NADAC) survey, published by CMS. HCPCS drug pricing codes from Medicare Part B Drug Average Sales Price file.

What NADAC means: The average price pharmacies pay to acquire this drug from wholesalers. Hospital charges for the same drug are typically higher due to facility fees, compounding, and administration costs.

Limitations: NADAC reflects pharmacy acquisition cost, not patient out-of-pocket cost. Insurance copays, formulary tiers, and manufacturer rebates affect what patients actually pay.